BCIQ Profiles

Company Profile Report
0830 QTs
BioCentury & Getty Images

Product Development

Aug. 30 Quick Takes: Pfizer’s abrocitinib beats Dupixent in atopic dermatitis Phase III

Dupixent meets in pediatric dermatitis, Revelation merges with SPAC, plus Bone, Meletios

Aug 31, 2021 | 1:14 AM GMT

Pfizer Inc. (NYSE:PFE) said JAK-1 inhibitor abrocitinib was superior to marketed therapy Dupixent dupilumab, an IL-4R and IL-13

Read the full 548 word article

How to gain access

Continue reading with a
two-week free trial.